Filtered By:
Condition: Diabetes
Countries: USA Health
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 465 results found since Jan 2013.
Erectile Dysfunction Associated With Use of E-Cigarettes, Report Finds
This study highlights a novel finding that ENDS use could have serious implications on men’s se xual health.”El-Shahawy and colleagues analyzed data collected from December 2016 to January 2018 as part of thePopulation Assessment of Tobacco or Health (PATH) study —a national longitudinal study of tobacco use and how it affects the health of people in the United States. The researchers specifically focused on male participants 20 years and older who responded to questions about erectile dysfunction; their use of ENDS; current or past history of smoking; and previous diagnoses of diabetes, hypertension, high cholestero...
Source: Psychiatr News - December 7, 2021 Category: Psychiatry Tags: American Journal of Preventive Medicine E-cigarettes erectile dysfunction PATH Study Source Type: research
Cerebrovascular Risk Profiles in a Saudi Arabian Cohort of Young Stroke Patients
Conclusion: Cerebrovascular risk profiles and stroke etiologies in our cohort of young stroke patients differ from those of previous cohorts, suggesting the need for tailored prevention strategies that take into account local epidemiological data on cerebrovascular health.
Source: Frontiers in Neurology - November 12, 2021 Category: Neurology Source Type: research
Couple and family interventions for high mortality health conditions: A strategic review (2010 –2019)
AbstractThe earliest publications in the field of marriage and family therapy introduced interventions conducted with families experiencing complex health conditions. This strategic review captures an evaluation of efficacy for 87 couple and family interventions published between 2010 and 2019 with a focus on the leading causes of mortality in the United States. These health conditions include chromosomal anomalies and accidents with infants aged 0 –4 years; accidents and cancer among children aged 5–14; accidents among adolescents aged 15–24; and heart disease, cancer, accidents, chronic lower respiratory diseases,...
Source: Journal of Marital and Family Therapy - November 6, 2021 Category: Psychiatry & Psychology Authors: Angela L. Lamson,
Jennifer L. Hodgson,
Keeley J. Pratt,
Tai J. Mendenhall,
Alison G. Wong,
Erin M. Sesemann,
Braden J. Brown,
Erika S. Taylor,
Jacqueline M. Williams ‐Reade,
Daniel J. Blocker,
Jennifer Harsh Caspari,
Max Zubatsky,
Matthew P. Tags: ORIGINAL ARTICLE Source Type: research
Meta ‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
AbstractThe advent of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) ushered in a new era of dyslipidemia pharmacotherapy. The first two antibodies targeting PCSK9 (evolocumab, alirocumab) approved by the United States Food and Drug Administration (FDA) provided significant and sustained reductions in atherogenic lipids and a reduced risk of atherosclerotic cardiovascular disease (ASCVD) events. More recently, phase 3 trials of inclisiran —a small interfering RNA-based agent targeting PCSK9—reported similar lipid-lowering effects and preliminary evidence of ASCVD risk reduction, a...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 30, 2021 Category: Drugs & Pharmacology Authors: Azita H. Talasaz,
Ai ‐Chen (Jane) Ho,
Fawzia Bhatty,
Rachel A. Koenig,
Dave L. Dixon,
William L. Baker,
Benjamin W. Van Tassell Tags: TI ON ADVANCES IN CARDIOVASCULAR PHARMACOTHERAPY Source Type: research
IJERPH, Vol. 18, Pages 11284: Examining Predictors of Myocardial Infarction
This study analyzed predictors of myocardial infarction (MI) for those aged 35 and older based on demographic, socioeconomic, geographic, behavioral, and risk factors, as well as access to healthcare variables using the Center for Disease (CDC) Control Behavioral Risk Factor Surveillance System (BRFSS) survey for the year 2019. Multiple quasibinomial models were generated on an 80% training set hierarchically and then used to forecast the 20% test set. The final training model proved somewhat capable of prediction with a weighted F1-Score = 0.898. A complete model based on statistically significant variables using the enti...
Source: International Journal of Environmental Research and Public Health - October 27, 2021 Category: Environmental Health Authors: Diane Dolezel Alexander McLeod Larry Fulton Tags: Article Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Meta ‐Analysis of Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD
ConclusionThese findings suggest a class effect for favorable lipid changes and a low risk of serious adverse events among pharmacologic agents targeting PCSK9. Although there is compelling evidence that PCSK9-targeting agents reduce the risk of some cardiovascular outcomes, adequately powered studies with longer follow-up may be needed to fully characterize the magnitude of benefits across the cardiovascular spectrum.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 17, 2021 Category: Drugs & Pharmacology Authors: Azita H. Talasaz,
Ai ‐Chen (Jane) Ho,
Fawzia Bhatty,
Rachel A. Koenig,
Dave L. Dixon,
William L. Baker,
Benjamin W. Van Tassell Tags: TI ON ADVANCES IN CARDIOVASCULAR PHARMACOTHERAPY Source Type: research
Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study
CONCLUSION: Beyond excess deaths alone, the COVID-19 pandemic imposed a greater life expectancy burden on persons aged 25 to 64 years, including those with average or above-average life expectancies, and a disproportionate burden on Black and Hispanic communities.PRIMARY FUNDING SOURCE: National Institute on Aging.PMID:34543588 | DOI:10.7326/M21-2239
Source: Annals of Internal Medicine - September 20, 2021 Category: Internal Medicine Authors: Julian Reif Hanke Heun-Johnson Bryan Tysinger Darius Lakdawalla Source Type: research
Understanding the impact of psychosocial working conditions on workers ’ health: we have come a long way, but are we there yet?
This issue of the journal includes a meta-review, ie, a systematic review of systematic reviews, summarizing the published evidence on the associations between exposure to adverse psychosocial working conditions and risk of developing diseases or disorders during the past 20 years (1). Although the authors allowed inclusion of reviews reporting results from cross-sectional studies, the majority of the included reviews were restricted to prospective cohort studies – the gold standard method in psychosocial occupational epidemiology. We commend the authors for their succinct summary of the current knowledge on the topic, e...
Source: Scandinavian Journal of Work, Environment and Health - September 3, 2021 Category: Occupational Health Tags: Editorial Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Trends in Meeting the Aerobic Physical Activity Guideline Among Adults With and Without Select Chronic Health Conditions, United States, 1998-2018
CONCLUSIONS: Although rising trends in physical activity levels among adults with chronic health conditions are encouraging for improving chronic disease management, current prevalence remains low, particularly among older adults. Increasing physical activity should remain a priority for chronic disease management and control.PMID:34465653 | DOI:10.1123/jpah.2021-0178
Source: Journal of Physical Activity and Health - September 1, 2021 Category: Sports Medicine Authors: John D Omura Eric T Hyde Giuseppina Imperatore Fleetwood Loustalot Louise Murphy Mary Puckett Kathleen B Watson Susan A Carlson Source Type: research
